Abstract:AIM:To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC).METHODS:Two irinotecan- and fluorouracil-based regimens, FOLFIRI and IFL, were selected as second-line therapy for 138 Chinese mCRC patients. Genomic DNA was extracted from peripheral blood samples before treatment. UGT1A1 and TS gene polymorphisms were determined by direct sequencing and restriction fragment length polymorphism, respectively. Gene polymorphisms of UGT1A1*28, UGT1A1*6 and promoter enhancer region of TS were analyzed. The relationship between genetic polymorphisms and clinical outcome, that is, response, toxicity and survival were assessed. Pharmacokinetic analyses were performed in a subgroup patients based on different UGT1A1 genotypes. Plasma concentration of irinotecan and its active metabolite SN-38 and inactive metabolite SN-38G were determined by high performance liquid chromatography. Differences in irinotecan and its metabolites between UGT1A1 gene variants were compared.RESULTS:One hundred and eight patients received the FOLFIRI regimen, 29 the IFL regimen, and one irinotecan monotherapy. One hundred and thirty patients were eligible for toxicity and 111 for efficacy evaluation. One hundred and thirty-six patients were tested for UGT1A1*28 and *6 genotypes and 125 for promoter enhancer region of TS. Patients showed a higher frequency of wild-type UGT1A1*28 (TA6/6) compared with a Caucasian population (69.9% vs 45.2%). No significant difference was found between response rates and UGT1A1 genotype, although wild-type showed lower response rates compared with other variants (17.9% vs 24.2% for UGT1A1*28, 15.7% vs 26.8% for UGT1A1*6). When TS was considered, the subgroup with homozygous UGT1A1*28 (TA7/7) and non-3RG genotypes showed the highest response rate (33.3%), while wild-type UGT1A1*28 (TA6/6) with non-3RG only had a 13.6% response rate, but no significant difference was found. Logistic regression showed treatment duration was closely linked to clinical response. In toxicity comparison, UGT1A1*28 TA6/6 was associated with lower incidence of grade 2-4 diarrhea (27.8% vs 100%), and significantly reduced the risk of grade 4 neutropenia compared with TA7/7 (7.8% vs 37.5%). Wild-type UGT1A1*6 (G/G) tended to have a lower incidence of grade 3/4 diarrhea vs homozygous mutant (A/A) genotype (13.0% vs 40.0%). Taking UGT1A1 and TS genotypes together, lower incidence of grade 2-4 diarrhea was found in patients with non-3RG TS genotypes, when TA6/6 was compared with TA7/7 (35.3% vs 100.0%). No significant association with time to progression (TTP) and overall survival (OS) was observed with either UGT1A1 or TS gene polymorphisms, although slightly longer TTP and OS were found with UGT1A1*28 (TA6/6). Irinotecan PK was investigated in 34 patients, which showed high area under concentration curve (AUC) of irinotecan and SN-38, but low AUC ratio (SN-38G / SN-38) in those patients with UGT1A1*28 TA7/7.CONCLUSION:A distinct distribution pattern of UGT1A1 genotypes in Chinese patients might contribute to relatively low toxicity associated with irinotecan and 5-fluorouracil in mCRC patients.

Abstract 2203: Characterization of Raloxifene Glucuronidation and the Role of UGT Genotypes on Raloxifene Metabolite Profiles in Vivo.

Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.

Functional Significance Of Udp-Glucuronosyltransferase Variants In The Metabolism Of Active Tamoxifen Metabolites

Association of Bone Metabolism Related Genes Polymorphisms with the Effect of Raloxifene Hydrochloride on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Osteoporosis.

Genotype-phenotype correlation between the polymorphic UDP-glucuronosyltransferase 2B7 and O-glucuronidation of the major active metabolites of tamoxifen

Characterization Of 17-Dihydroexemestane Glucuronidation: Potential Role Of The Ugt2b17 Deletion In Exemestane Pharmacogenetics

Differences between polymorphic variants of UDP-glucuronosyltransferases (UGTs) active against the major tamoxifen metabolite, endoxifen: Potential impact on individual response of TAM treatment.

Glucuronidation of Tamoxifen Metabolites by UGTs. Potential Role UGTs Variants in Tamoxifen Metabolism

Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention: Focus on Tamoxifen and Aromatase Inhibitors

Abstract 3589: Characterization of 17-dihydroexemestane glucuronidation. A role for the UGT2B17 deletion in exemestane pharmacogenetics

Glucuronidation Of Active Tamoxifen Metabolites By The Human Udp Glucuronosyltransferases

Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women

Raloxifene increases the risk of gastroesophageal reflux disease, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

Glucuronidation of the Active Metabolites of Tamoxifen by Human Liver Microsome and Individual UDP-glucuronosyltransferases (Ugts)

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

[Raloxifene and breast: from the SERMs concept to its place in clinical practice]

Alendronate Versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials.